Mindfulness experience for young people at risk of psychosis
Part of Mental health clinical trials.
This study explores how young people who are at high risk for psychosis or have had a first episode experience mindfulness. It uses interviews to understand their personal experience, which could help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 30 years old.
- You are at ultra-high risk for psychosis or have had a first episode of psychosis, based on a specific assessment (CAARMS scale).
- This condition must also affect your daily life, such as work, school, or social activities.
- You have not had a previous diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder.
- You have not taken antipsychotic medication for more than 12 months.
- You must be able to speak French well enough to take part in an interview that will be audio recorded.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a mindfulness program can help prevent psychosis in young people who are at ultra high risk. The goal is to see if learning mindfulness skills can protect your mental health and keep symptoms from getting worse.
This trial tests a telehealth (video/phone) version of cognitive behavioral therapy to help young people who are at risk for developing psychosis. It may help by teaching skills to reduce symptoms and improve coping, with support from a key family or close person.
This study tests a new program to help young people who have early signs of psychosis and have had thoughts of suicide or tried to harm themselves. The program works with the young person and a family member or caregiver to improve support and reduce suicide risk.
This study is testing a new French version of a questionnaire (SPI-CY) that helps doctors better understand early signs of psychosis in teenagers. If you are 12 to 17 and already being checked for these signs, you may be able to help improve the tool.
This study tests whether a medication called cannabidiol (a non-intoxicating compound from cannabis) can help reduce symptoms and prevent progression in young people at clinical high risk for psychosis. Participants will receive either the study drug or a placebo (a pill with no active ingredient) and will be followed to see how they respond.
This study tests a support program for young people in Tunisia who show early signs of possible psychosis. It aims to help them before more serious symptoms develop.
Hear when a new Clinical High Risk for Psychosis (CHR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.